KymaThera, a precision therapeutics startup developing medicines for cancer and other diseases, seeks to raise roughly $75 million, Axios Pro has learned.
State of play: The effort comes amid Eli Lilly's $2.3 billion acquisition of KymaThera peer Ajax Therapeutics.
